Diplomat Pharmacy (DPLO) Upgraded at ValuEngine

ValuEngine upgraded shares of Diplomat Pharmacy (NYSE:DPLO) from a hold rating to a buy rating in a report issued on Friday, ValuEngine reports.

A number of other research analysts have also recently issued reports on DPLO. Zacks Investment Research cut Diplomat Pharmacy from a hold rating to a strong sell rating in a report on Friday. Credit Suisse Group cut their price target on Diplomat Pharmacy from $10.00 to $8.00 and set a neutral rating for the company in a report on Tuesday, April 2nd. Guggenheim assumed coverage on Diplomat Pharmacy in a report on Wednesday, April 17th. They set a neutral rating and a $6.00 price objective for the company. Morgan Stanley dropped their price objective on Diplomat Pharmacy from $10.00 to $8.00 and set an equal weight rating for the company in a report on Monday, March 18th. Finally, Mizuho boosted their price objective on Diplomat Pharmacy from $6.00 to $8.00 and gave the stock a reduce rating in a report on Monday, March 18th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of $10.25.

Diplomat Pharmacy stock opened at $5.70 on Friday. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.00 and a quick ratio of 0.62. Diplomat Pharmacy has a 12-month low of $4.99 and a 12-month high of $28.74. The stock has a market capitalization of $425.85 million, a P/E ratio of 28.50 and a beta of 0.69.

Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.07 by ($0.26). Diplomat Pharmacy had a negative net margin of 5.85% and a positive return on equity of 1.38%. The business had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the prior year, the firm earned ($0.01) earnings per share. The business’s quarterly revenue was down 6.4% compared to the same quarter last year. As a group, sell-side analysts predict that Diplomat Pharmacy will post -0.61 EPS for the current fiscal year.

A number of large investors have recently made changes to their positions in DPLO. Bank of New York Mellon Corp raised its holdings in Diplomat Pharmacy by 97.5% during the 4th quarter. Bank of New York Mellon Corp now owns 1,682,590 shares of the company’s stock worth $22,648,000 after purchasing an additional 830,436 shares during the last quarter. Advisory Services Network LLC acquired a new position in shares of Diplomat Pharmacy during the 4th quarter worth about $8,062,000. FMR LLC grew its position in shares of Diplomat Pharmacy by 61.8% during the 4th quarter. FMR LLC now owns 1,189,312 shares of the company’s stock worth $16,008,000 after buying an additional 454,112 shares during the period. Stephens Inc. AR acquired a new position in shares of Diplomat Pharmacy during the 1st quarter worth about $2,424,000. Finally, Dimensional Fund Advisors LP grew its position in shares of Diplomat Pharmacy by 22.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,128,358 shares of the company’s stock worth $28,650,000 after buying an additional 395,246 shares during the period. 74.96% of the stock is owned by hedge funds and other institutional investors.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Further Reading: Convertible Shares

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.